Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.99
- Piotroski Score 5.00
- Grade Buy
- Symbol (IBRX)
- Company ImmunityBio, Inc.
- Price $4.74
- Changes Percentage (3.84%)
- Change $0.18
- Day Low $4.58
- Day High $4.75
- Year High $10.53
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.08
- Trailing P/E Ratio -5.65
- Forward P/E Ratio -5.65
- P/E Growth -5.65
- Net Income $-583,196,000
Income Statement
Quarterly
Annual
Latest News of IBRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares
Inhibrx Biosciences has 7 investors with a majority stake of 50%. Institutions hold 43% ownership, facing the biggest gain or loss. Hedge funds and individuals also hold significant stakes, with Vikin...
By Yahoo! Finance | 2 weeks ago -
Inhibrx: The Biotech Spinoff Poised For Big Gains
An experienced investor shares insights on finding hidden gems in overlooked areas of the market, focusing on spinoff companies like Inhibrx Biosciences. With innovative biotech treatments targeting c...
By Forbes | 2 months ago -
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)
Inhibrx Biosciences Inc (NASDAQ:INBX) is a biotech company developing therapeutic candidates for various medical needs. Recent insider transactions show more buying than selling, indicating confidence...
By Yahoo! Finance | 2 months ago
